Anglo/Swedish global commercial sponsor AstraZeneca reports in APNews that it will present 20 abstracts including a late-breaking oral presentation on the full results of the Phase 3 cardiovascular (CV) outcomes trial (COVOT) DECLARE (Dapagliflozin Effect on Cardiovascular Events)-TIMI 58, the broadest SGLT2 inhibitor CVOT conducted to date, as well as new research from the AstraZeneca’s Renal & Metabolism (CVDM) therapy area at the American Heart Association (AHA) Scientific Sessions, Nov 10-12, 2018 in Chicago, IL.

 

Source: AP News

Pin It on Pinterest